DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
DarioHealth Corp.NASDAQ: DRIO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $8.12M fell 11.5% year over year, ahead of the -17.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 7.0% from the prior quarter. Over 3 fiscal years it compounded at -8.8% a year.
Context
- Selling, general & admin amounted to 158.9% of revenue in FY2025, down 14.3 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $43.89M (+23.5%) for the fiscal year ending Dec 2026, a step up from the -24.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.12M-7.0% QoQ
- Last fiscal yearDec 2025
- $35.53M-24.1% YoY
- LTMMar 2026
- $34.47M-17.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 35.53M USD
- Year-over-year change
- -24.1%
- 4-year CAGR
- -13.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.53M | -24.1% |
| FY2024 | 2024-12-31 | 46.83M | +12.0% |
| FY2023 | 2023-12-31 | 41.8M | -10.7% |
| FY2022 | 2022-12-31 | 46.82M | -24.9% |
| FY2021 | 2021-12-31 | 62.36M | — |
Selling, General & Admin vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 selling, general & admin of $34.47M is the 9th highest of the 11 companies compared; the peer median is $149.33M.
- Its year-over-year change of -17.2% is the 9th highest of 11, against a peer median of +5.3%.
- Selling, general & admin amounts to 162.7% of revenue for DRIO, versus a peer median of 66.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $555.96M | +4.1% | +13.9% | 67.4% | |
| LTM Mar 2026 | $537.7M | -3.2% | +1.5% | 64.9% | |
| LTM Mar 2026 | $290.1M | -3.4% | -12.3% | 40.5% | |
| LTM Mar 2026 | $203.36M | +34.2% | +6.1% | 21.5% | |
| LTM Mar 2026 | $166.18M | +30.2% | +2.2% | 51.9% | |
| LTM Mar 2026 | $132.48M | -17.6% | -4.2% | 82.8% | |
| LTM Mar 2026 | $88.42M | +83.1% | +48.1% | 178.3% | |
| LTM Mar 2026 | $83.82M | +6.5% | -1.0% | 95.4% | |
| LTM Mar 2026 | $34.47M | -17.2% | -8.8% | 162.7% | |
| LTM Mar 2026 | $17.68M | +91.0% | — | 962.7% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $1.78M | -48.3% | -6.4% | 18.2% |
| Peer median (excluding DRIO) | $149.33M | +5.3% | +1.5% | 66.1% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M |
| Cost of Revenue | 12.44M | 18M | 14.37M | 13.77M | 9.69M |
| Gross Profit | 8.07M | 9.66M | 5.98M | 13.27M | 12.67M |
| Gross Margin | 39.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Research & Development | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M |
| Selling, General & Admin | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M |
| Operating Expenses | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M |
| EBITDA | (70.02M) | (55.6M) | (54.38M) | (37.08M) | (34.69M) |
| EBITDA Margin | -341.3% | -201.0% | -267.2% | -137.1% | -155.2% |
| Operating Income | (76.49M) | (56.81M) | (56.19M) | (57.74M) | (36.66M) |
| Operating Margin | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Interest Income | 44K | 506K | 1.87M | 1.12M | 943K |
| Interest Expense | 84K | 2.68M | 645K | 96K | 3.36M |
| Other Income / Expenses | (235K) | (5.38M) | (3.17M) | 13.15M | (4.95M) |
| Income Before Tax | (76.73M) | (62.19M) | (59.36M) | (44.6M) | (41.61M) |
| Pre-Tax Margin | -374.1% | -224.9% | -291.7% | -164.9% | -186.1% |
| Income Tax Expense | 32K | 4K | 64K | (1.85M) | 105K |
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Net Margin | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (Basic) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| EPS (Diluted) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| Weighted Avg Shares | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
| Weighted Avg Shares (Diluted) | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.